Curex GLP-1 Weight Loss: Specific Patient Profiles That Should Avoid It

What Exactly Is Curex, and How Does Its Prescribing Model Work?

Curex operates as an asynchronous or synchronous telehealth platform that connects patients with licensed prescribers who write for compounded semaglutide, tirzepatide, or related GLP-1 receptor agonists. The visit is cash-pay, meaning no insurance billing. Patients complete an intake questionnaire, receive a video or messaging consultation, and, if approved, receive compounded injectable medication by mail from a partnered compounding pharmacy.

The compounded vs. Branded drug distinction matters clinically

FDA-approved branded semaglutide products, Ozempic (Novo Nordisk) and Wegovy (Novo Nordisk), carry full New Drug Application approval and are manufactured under Current Good Manufacturing Practice standards. Compounded semaglutide is prepared by 503A or 503B pharmacies and is not FDA-approved as a finished drug product. The FDA stated in May 2023 that it cannot verify the safety or effectiveness of compounded versions, and it issued a 2024 guidance update warning consumers about quality and dosing inconsistencies in compounded semaglutide.

How Curex earns revenue

Because Curex does not accept insurance, the out-of-pocket cost typically ranges between $199 and $399 per month depending on the medication dose and pharmacy partner. That business model creates a structural incentive to approve as many patients as possible. Independent readers should weigh that incentive when evaluating how rigorously Curex screens for contraindications.

Hard Medical Contraindications: Patients Who Must Not Use Any GLP-1 Program, Including Curex

These contraindications apply to the drug class, not Curex specifically. No telehealth platform, cash-pay or otherwise, should prescribe semaglutide to these patients.

Medullary thyroid carcinoma and MEN 2

All FDA-approved GLP-1 receptor agonists carry a black-box warning for thyroid C-cell tumors. The Wegovy prescribing information states: "Semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in both genders of rats and mice." The FDA label available at accessdata.fda.gov lists a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) as an absolute contraindication.

Telehealth intake questionnaires that rely only on self-report may miss patients who are unaware of a family history of MTC. Any patient with even a suspected first-degree relative with thyroid cancer should get in-person genetic counseling before starting a GLP-1.

Acute or chronic pancreatitis

GLP-1 receptor agonists have been associated with acute pancreatitis in post-marketing data. The FDA label for semaglutide states the drug should not be initiated in patients with a history of pancreatitis. A 2019 meta-analysis in JAMA Internal Medicine covering 55 randomized trials found that GLP-1 receptor agonist use was associated with a statistically significant increase in any acute pancreatitis event (OR 1.78, 95% CI 1.13 to 2.80) compared with placebo [1]. Patients with chronic pancreatitis, pancreatic exocrine insufficiency, or prior pancreatic surgery are poor candidates.

Diabetic retinopathy with rapid glucose lowering

In the SUSTAIN-6 cardiovascular outcomes trial (N=3,297), patients with semaglutide experienced a significantly higher rate of diabetic retinopathy complications compared with placebo (3.0% vs. 1.8%, P<0.001) [2]. The mechanism may relate to the speed of HbA1c reduction. Patients with pre-existing diabetic retinopathy should have an ophthalmology evaluation before starting any GLP-1.

Severe renal impairment (eGFR <15 mL/min/1.73m²)

The prescribing information for semaglutide advises caution in patients with end-stage renal disease. Volume depletion from nausea and vomiting, a common side effect, can precipitate acute kidney injury in patients with already reduced renal reserve. Patients on dialysis or with eGFR <15 require nephrologist involvement, not a quick async telehealth visit.

Clinical Profiles Where Curex's Telehealth Model Creates Specific Risk

Beyond absolute drug contraindications, certain patient profiles are a poor fit for Curex's asynchronous or minimally supervised model specifically.

Patients on insulin or sulfonylureas

GLP-1 receptor agonists lower blood glucose. When combined with insulin (glargine, detemir, lispro) or sulfonylureas (glipizide, glimepiride), the combined effect can produce clinically significant hypoglycemia. The STEP-2 trial (N=1,210) tested semaglutide 2.4 mg in patients with type 2 diabetes and found mean HbA1c reductions of 1.6 percentage points versus 0.4 for placebo [3]. Without dose adjustments to background diabetes medications by a physician who can review a current medication list and recent glucose logs, hypoglycemic episodes are a real risk. Curex's quick intake model may not capture full diabetes medication reconciliation.

Patients with a prior history of eating disorders

The Endocrine Society's 2023 obesity guidelines state that clinicians should screen for eating disorder history before initiating pharmacotherapy for weight loss [4]. GLP-1 agents cause significant appetite suppression. In patients with a history of restrictive eating disorders such as anorexia nervosa, that appetite-suppressive effect may reinforce disordered eating behaviors. A brief telehealth questionnaire is unlikely to perform the validated screening (e.g., the SCOFF questionnaire) needed to identify this risk.

Patients under age 18 (or under 12 for tirzepatide)

Wegovy (semaglutide 2.4 mg) received FDA approval for chronic weight management in adolescents aged 12 and older in December 2022. Compounded semaglutide has no pediatric approval at any age. Any platform prescribing compounded GLP-1 agents to patients under 18 is operating outside established safety data. Parents seeking GLP-1 therapy for minors should work exclusively with board-certified pediatric endocrinologists at accredited institutions.

Patients who are pregnant or planning pregnancy within 2 months

The FDA label advises discontinuing semaglutide at least 2 months before planned pregnancy due to potential fetal harm seen in animal reproduction studies. A 2023 case series published in The New England Journal of Medicine documented unintended pregnancies in women on GLP-1 agents, possibly because rapid weight loss can restore ovulatory cycles in women with obesity-related anovulation [5]. A cash-pay telehealth platform without access to a patient's obstetric or gynecologic records may not adequately counsel on this risk.

Patients with a prior gastroparesis diagnosis

GLP-1 receptor agonists delay gastric emptying. That mechanism contributes to satiety but in patients with pre-existing gastroparesis (whether idiopathic or diabetic), it can worsen symptoms substantially. A 2023 case-control study in Gastroenterology found that GLP-1 receptor agonist use was associated with a 3.67-fold increased risk of gastroparesis diagnosis (95% CI 1.15 to 11.7) compared with non-users [6]. Any patient with documented slow gastric emptying on scintigraphy or an empiric gastroparesis diagnosis should not start a GLP-1 without GI specialist input.

Is Curex Legit? Examining Regulatory Standing and Complaint Patterns

"Legit" covers two separate questions: (1) Is Curex a legally operating telehealth platform? (2) Does it operate with consistent clinical quality?

Legal operating status

Curex appears to hold the necessary telehealth business registrations in the states where it operates and partners with state-licensed prescribers. It is not on the FDA's list of companies warned for selling unapproved drug products as of January 2025. The compounding pharmacies it partners with must hold 503A or 503B status; patients should ask Curex directly for the name of the fulfilling pharmacy and verify that pharmacy's FDA registration independently at fda.gov.

BBB profile and complaint themes

The Better Business Bureau lists Curex but shows it as not accredited. Consumer complaints on record cluster around three themes: billing disputes after free-trial periods, difficulty canceling recurring subscriptions, and delayed shipping of medication. None of those complaint categories are clinical safety issues in isolation, but billing opacity and cancellation difficulty do suggest the platform prioritizes retention over patient autonomy. The FDA does not regulate telehealth platform billing practices; state attorney general offices and the FTC handle those complaints.

LegitScript verification

LegitScript is the certification body that major advertising platforms use to verify online pharmacies and telehealth companies. As of this writing, Curex does not appear in LegitScript's verified telehealth provider database. That absence does not make Curex illegal, but it does mean the company has not submitted to LegitScript's independent audit of prescribing practices and pharmacy sourcing. For patients who weigh third-party verification, that matters.

A practical verification checklist before using any GLP-1 telehealth platform

Before committing to Curex or any cash-pay GLP-1 service, patients should confirm five things:

1. The platform discloses the full name and NCPDP/NPI number of the dispensing pharmacy.
2. The prescriber holds an active license in the patient's state (verify at the relevant state medical board website).
3. The platform performs a medication reconciliation that includes current diabetes, thyroid, and cardiovascular drugs.
4. The platform provides a clear cancellation and refund policy in writing before the first charge.
5. The compounding pharmacy is registered as a 503B outsourcing facility or is a licensed 503A pharmacy with a valid patient-specific prescription.

What the Evidence Actually Says About Compounded Semaglutide Safety

Branded semaglutide trials have generated a large and well-controlled safety dataset. The STEP-1 trial (N=1,961) showed a mean weight loss of 14.9% at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo, with adverse events (primarily nausea and vomiting) leading to discontinuation in 7.0% of active-drug patients [7]. The SELECT trial (N=17,604) confirmed cardiovascular safety, showing a 20% relative risk reduction in major adverse cardiovascular events in patients with obesity but without diabetes [8].

Those data apply to branded, FDA-approved semaglutide manufactured under CGMP.

Compounded semaglutide has no equivalent trial dataset. The FDA noted in a 2024 safety communication that it received adverse event reports involving compounded semaglutide products, including reports of hospitalizations. Dose errors are a specific concern: compounded semaglutide may come as a multi-dose vial requiring patient self-titration, whereas the branded auto-injector uses a fixed-dose pen. Self-titration errors can result in doses far outside the studied range.

Patients who have a medical indication for semaglutide and can access branded Wegovy or Ozempic through a manufacturer copay program (Novo Nordisk's NovoCare offers Wegovy at $0/month for eligible patients under 185% of the federal poverty level) are generally better served by the branded product.

Specific Conditions That Interact With GLP-1 Drugs and Require Specialist Input

Gallbladder disease

Rapid weight loss of any cause increases cholelithiasis risk. GLP-1 agents compound that risk by reducing gallbladder motility. In STEP-1, cholecystitis occurred in 1.6% of semaglutide patients versus 0.7% of placebo patients [7]. Patients with known gallstones, prior cholecystitis, or biliary sludge on ultrasound should have a gastroenterology or surgery consultation before starting.

Heart failure with reduced ejection fraction (HFrEF)

The 2024 American Heart Association/ACC guideline update notes that GLP-1 receptor agonists may be used in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) based on the STEP-HFpEF trial [9]. However, for HFrEF (ejection fraction <40%), the evidence is less clear and some mechanistic concern exists around heart rate elevation. A cardiologist should be involved.

Thyroid nodules of indeterminate cytology

Patients who have known thyroid nodules classified as Bethesda III or higher on fine-needle aspiration cytology should not start a GLP-1 agent until the nodule's nature is clarified by endocrinology. The black-box thyroid warning applies.

How to Raise Concerns or File a Complaint About Curex

If you have had a negative clinical or billing experience with Curex, four formal channels exist:

• FDA MedWatch: Report adverse events from any drug, including compounded medications, at fda.gov/safety/medwatch.
• State medical board: File complaints about prescriber conduct at the medical board in the state where your prescribing provider is licensed.
• FTC: Report deceptive billing or subscription practices at the Federal Trade Commission's complaint portal.
• State attorney general: Handles consumer protection complaints about telehealth billing practices.

None of those channels are monitored by HealthRX, and we have no affiliation with Curex.

Practical Alternatives for Patients Who Cannot or Should Not Use Curex

Patients who fall into any of the contraindicated or high-risk profiles above still have legitimate options for evidence-based weight management.

Patients with type 2 diabetes who need semaglutide should pursue it through their primary care physician or endocrinologist, who can access manufacturer patient assistance programs and monitor labs. The American Diabetes Association's 2024 Standards of Care [10] recommend GLP-1 receptor agonists as preferred agents in patients with type 2 diabetes and established cardiovascular disease, chronic kidney disease, or heart failure.

Patients who have contraindications to GLP-1 agents entirely may be candidates for phentermine-topiramate extended-release (Qsymia) or naltrexone-bupropion (Contrave), both FDA-approved for chronic weight management and available through standard telehealth platforms without the compounding concerns.

Patients whose primary barrier is cost should check NovoCare (Novo Nordisk's assistance program), the Lilly Cares Foundation (for tirzepatide/Zepbound), and GoodRx before defaulting to compounded products.